Tag Archives: BIIB

Top 10 Tech Stocks To Own Right Now

Apple Inc. is set to report its Q2 2017 earnings on May 2. Is AAPL stock a good buy going into the earnings release?
wallpaperrs.com

Shares of Cupertino,California-based tech giant,Apple Inc.(NASDAQ:AAPL)have been in a solid uptrend over the last few months. AAPL stock price closed the last trading session at a price of $143.79, registering a year-to-date gain of 24.15%. Apple stock has handsomely outperformed the Nasdaq Composite (INDEX:COMPX), which is up 12.36% YTD as well as the broader S&P 500 (INDEX:SPAL), which has gained 6.7% in the same timeframe. The Tim Cook-led company is set to report its Q2 2017 earnings after the market close on May 2. What should investors watch out for in the upcoming earnings report? Will the upcoming Q2 2017 earnings report send AAPL stock flying higher?

Top 10 Tech Stocks To Own Right Now: Trina Solar Limited(TSL)

Advisors’ Opinion:

  • [By Elizabeth Balboa]

    The firm has a Sell rating on First Solar, JA Solar Holdings and Trina Solar Limited (ADR) (NYSE: TSL). It maintains a NC rating on SunPower Corporation, Canadian Solar and JinkoSolar Holding.

  • [By Roberto Pedone]

    Another potential earnings short-squeeze candidate is integrated solar-power products maker Trina Solar (TSL), which is set to release numbers on next Monday before the market open. Wall Street analysts, on average, expect Trina Solar to report revenue of $645.68 million on earnings of 15 cents per share.

    The current short interest as a percentage of the float for Trina Solar is extremely high at 24.5%. That means that out of the 76.94 million shares in the tradable float, 18.88 million shares are sold short by the bears. If the bulls get the earnings news they’re looking for, then shares of TSL could easily rip sharply higher post-earnings as the bears move to cover some of their positions.

    From a technical perspective, TSL is currently trending below both its 50-day and 200-day moving averages, which is bearish. This stock recently formed a double bottom chart pattern at $8.67 to $9.04 a share. Shares of TSL have now started to rebound off those support levels and it’s quickly moving within range of triggering a major breakout trade post-earnings above some key near-term overhead resistance levels.

    If you’re bullish on TSL, then I would wait until after its report and look for long-biased trades if this stock manages to break out above some near-term overhead resistance levels at $10.72 to $11.19 a share and then above its 50-day moving average of $11.17 a share with high volume. Look for volume on that move that hits near or above its three-month average action of 5.17 million shares. If that breakout materializes post-earnings, then TSL will set up to re-test or possibly take out its next major overhead resistance levels at its 200-day moving average of $12.49 to $14 a share, or even $14.50 to $15 a share.

    I would avoid TSL or look for short-biased trades if after earnings it fails to trigger that breakout and then drops back below some near-term support levels at $10 a share to those double bottom support levels at $9.04 to $8

  • [By Spencer Israel]

    Axiom Capital Managing Director Gordon Johnson upgraded the entire alternative energy sector from Market Underweight to Market Overweight and upgraded SolarCity Corp (NASDAQ: SCTY) from Sell to Hold and Trina Solar Limited (ADR) (NYSE: TSL), Yingli Green Energy Holding Co Ltd (ADR) (NYSE: YGE) and JA Solar Holdings Co., Ltd. (ADR) (NASDAQ: JASO) from Sell to Buy.

Top 10 Tech Stocks To Own Right Now: Polycom Inc.(PLCM)

Advisors’ Opinion:

  • [By Emily Stewart]

     Polycom (PLCM) is Soros’ top tech holding. As of the end of the second quarter, he owns 7.9 million shares valued at $89.2 million.

    Polycom provides collaboration solutions for voice, video, and content sharing. It has a $1.7 billion market cap and trades at a P/E of 73.24.

Top 10 Tech Stocks To Own Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Biogen (BIIB)

    Biogen discovers, develops and delivers innovative therapies for the treatment of neurodegenerative diseases and autoimmune disorders.

  • [By George Budwell]

    Shares of theDanish drugmaker Forward Pharma A/S (NASDAQ:FWP) gained 48.2% yesterday as the result of a settlement and licensing deal with Biogen (NASDAQ:BIIB)involving an ongoing patent dispute over the multiple sclerosis drug Tecfidera. Per the terms of the deal, Biogen will fork overa non-refundable$1.25 billion licensing fee, and possibly pay 10% to 20% royalties on Tecfidera’snet sales to Forward starting in 2021.

  • [By Chris Lange]

    Biogen Inc. (NASDAQ: BIIB) had its short interest increase to 2.63 million shares from the previous 2.36 million. The stock closed Friday at $305.20, within a 52-week range of $223.02 to $333.65.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Thursday was Biogen Inc. (NASDAQ: BIIB) which traded down 4.6% at $279.08. The stocks 52-week range is $223.02 to $333.65. Volume was 3.4 million versus the daily average of 1.6 million shares.

Top 10 Tech Stocks To Own Right Now: Cray Inc(CRAY)

Advisors’ Opinion:

  • [By Giulio Prisco]

    Microsoft (NSDQ:MSFT), supercomputer maker Cray (NSDQ:CRAY), and the Swiss National Supercomputing Centre (CSCS), a world-class scientific computing center, announced the results of a deep learning collaboration that expands the horizons of running Artificial Intelligence (AI), Machine Learning (ML), and in particular Deep Learning (an especially promising branch of ML) applications, using Microsoft software and Cray supercomputers.

  • [By Lisa Levin]

    Tuesday afternoon, the technology sector proved to be a source of strength for the market. Leading the sector was strength from Cray Inc. (NASDAQ: CRAY) and Mellanox Technologies, Ltd. (NASDAQ: MLNX).

  • [By Peter Graham]

    The Q4 2016 earnings report for small capsupercomputer stock Cray Inc (NASDAQ: CRAY) is scheduled forafter the market closes onWednesday (February 8th). Back in 2012, Cray Inc was inour SmallCap Network Elite Opportunity (SCN EO) portfolioasa potentially goodlow risk longer-term play as shares were trading at the $12 level and eventually hit $40+ per share before coming back down to earth last year.

  • [By Jim Robertson]

    Cray Inc. (CRAY) has been one of those feast or famine small caps that have either made traders and investors a lot of money in recent years – or simply frustrated those who’ve held it for quite some time. However, at this point we think CRAY offers an attractive risk/reward opportunity on a long-term basis for investors interested in exposure to big data analytics and specifically super-computing – a growing need for large enterprise and institutions all over the world

Top 10 Tech Stocks To Own Right Now: GRAVITY Co. Ltd.(GRVY)

Advisors’ Opinion:

  • [By Cooper Creagan]

    For example, if you had taken five minutes to set up a Night Trade on Gravity Co. (Nasdaq: GRVY) in October, you could’ve tripled your money, and then some.

  • [By Lisa Levin]

    Shares of Gravity Co., LTD. (ADR) (NASDAQ: GRVY) were down 13 percent to $49.03 following Q3 results. Gravity posted Q3 earnings of $0.34 per share on sales of $20.76 million.

  • [By Lisa Levin]

    Gravity Co., LTD. (ADR) (NASDAQ: GRVY) shares shot up 111 percent to $9.61 after the company reported Q3 results. GRAVITY reported Q3 earnings of $0.74 per share on sales of $13.143 million.

  • [By Peter Graham]

    While small cap gaming stocks Gravity Co. LTD (NASDAQ: GRVY), Inspired Entertainment (NASDAQ: INSE) and SPYR Inc (OTCQB: SPYR) may not be well know to investors, their games are well known to gamers.

Top 10 Tech Stocks To Own Right Now: Autohome Inc.(ATHM)

Advisors’ Opinion:

  • [By R. Chandrasekaran]

    The following stocks are rated with Neutral:

    JD.Com Inc(ADR) (NASDAQ: JD). Vipshop Holdings Ltd – ADR (NYSE: VIPS). Autohome Inc (ADR) (NYSE: ATHM). SouFun Holdings Ltd (NYSE: SFUN). Leju Holdings Ltd (ADR) (NYSE: LEJU).
    Underweight Names

    The following stocks are rated Underweight:

  • [By Monica Gerson]

    Autohome Inc (ADR) (NYSE: ATHM) is estimated to report its quarterly earnings at $1.68 per share on revenue of $1.05 billion.

    Vera Bradley, Inc. (NASDAQ: VRA) is expected to report its quarterly earnings at $0.05 per share on revenue of $106.75 million.

Top 10 Tech Stocks To Own Right Now: Fitbit, Inc.(FIT)

Advisors’ Opinion:

  • [By Tracey Ryniec]

    Fitbit is the latest tech gadget sensation. It has 22% of the wearables market and it looks like this holiday season could be huge for the company. Fitness and wellness are a big market globally which Fitbit is only beginning to tap. 

  • [By Leo Sun]

    Under Armour (NYSE:UA) (NYSE:UAA), Fitbit (NYSE:FIT), and GoPro (NASDAQ:GPRO) were all terrible stocks to own over the past year. Under Armour and Fitbit were both cut in half, and GoPro plummeted nearly 40%.

  • [By Brian Withers]

    Fitbit (NYSE:FIT)has been able to stay out of a price war in the wearables space. Over the last four years the company has deliberately expanded its product line enabling it to make 69% more revenue per device this year than in 2012.

Top 10 Tech Stocks To Own Right Now: AVG Technologies N.V.(AVG)

Advisors’ Opinion:

  • [By Igor Novgorodtsev]

    InterActiveCorp (IACI) bought Ask.com for $1.85 billion in 2005. The new Perion will be worth only about 40% of that. After the merger, Perion will leapfrog its much larger rivals: Babylon and AVG (AVG). Finally, Perion should be able to increase its operating margins as it can spread its SG&A costs over a much larger base (Conduit EBITDA margin is 32% vs. Perion’s 23%). Perion will keep its senior management team intact: Josef Mandelbaum will remain its CEO and Yacov Kaufman its CFO. Perion has successfully orchestrated a roll-up acquisitions of privately-held Sweetpacks and Smilebox, so I have high confidence that they know how to integrate a new business.

Top 10 Tech Stocks To Own Right Now: Internap Network Services Corporation(INAP)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Internap Corp (NASDAQ: INAP) got a boost, shooting up 28 percent to $2.32 as the company reported that it has raised $43 million in a common equity private placement.

  • [By Alex McGuire]

    These are the 10 best penny stocks that have seen the biggest returns over the last week (March 7 – March 14)…

    Penny StockCurrent PriceWeekly Gain (March 7 – March 14)Ocera Therapeutics Inc. (Nasdaq: OCRX)$1.47+147.1%Internap Corp. (Nasdaq: INAP)$3.28+41.4%Soligenix Inc. (Nasdaq: SNGX)$2.94+40%Navios Maritime Partners LP (NYSE: NMM)$2.63+37%QuickLogic Corp. (Nasdaq: QUIK)$2.14+30.5%Adamis Pharmaceuticals Corp. (Nasdaq: ADMP)$4.60+22.7EXCO Resources Inc. (NYSE: XCO)$0.65+20.5%Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC)$4.38+20.3%Hebron Technology Co. Ltd. (Nasdaq: HEBT)$3.99+19.1%Curis Inc. (Nasdaq: CRIS)$2.85+18.4%

    As a reminder, this is only a tracking metric of penny stocks trading on SEC-regulated exchanges like the Nasdaq and NYSE. Although these top penny stocks are safer than those trading on the pink sheets, we don’t recommend buying any of them without the proper amount of financial research.

  • [By Lisa Levin]

    Shares of Internap Corp (NASDAQ: INAP) got a boost, shooting up 13 percent to $2.97 on strong quarterly results. Stifel Nicolaus upgraded Internap from Hold to Buy and raised the price target from $2.00 to $5.50.

Top 10 Tech Stocks To Own Right Now: P.T. Telekomunikasi Indonesia Tbk.(TLK)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Wednesday, telecommunications services shares fell 0.45 percent. Meanwhile, top losers in the sector included Telekomunikasi Indones (Prsr)Tbk PT-ADR (NYSE: TLK), down 4 percent, and China Telecom Corporation Limited (ADR) (NYSE: CHA) down 2 percent.

Top 10 Biotech Stocks To Watch For 2018

Related AMGN Biotech In The Earnings Spotlight: Amgen, Celgene, Gilead Sciences Baird Isn't Changing Its Outlook On Amgen My Earnings Game Plan: July 25-27 (Seeking Alpha)

On CNBC’s Options Action, Carter Worth analyzed Amgen, Inc. (NASDAQ: AMGN) from a technical standpoint.

He said that the stock consistently outperformed iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB), which is in his opinion a basis for a bullish setup. Worth believes the stock is going to break out on the upside and reach its highs at $181.

Top 10 Biotech Stocks To Watch For 2018: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By ]

    All three are market-cap weighted — that is, the larger the company is, the more it impacts the overall performance of the index/fund. In the Nasdaq, for instance, the impact of any move in Apple, Microsoft or Amazon — which are weighted 12%, nearly 9% and nearly 8%, respectively — would be much more significant than the index impact of a much smaller position such as Amgen (Nasdaq: AMGN), with less than 2% of the index assets allocated.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) is expected to report its most recent quarterly results on Wednesday. The consensus estimates call for $3.00 in EPS and $5.61 billion in revenue. Shares closed trading at $160.41 on Friday, in a 52-week range of $133.64 to $184.21. The consensus price target is $185.13.

  • [By Maxx Chatsko]

    Shares of Radius Health (NASDAQ:RDUS) rose over 20% Monday morning after Amgen (NASDAQ:AMGN) announced worrisome complications were discovered during a phase 3 trial for its osteoporosis drug candidate, Evenity. While the drug candidate met its primary endpoint in a more than 4,000-patient phase 3 study, a high rate of serious heart-related side effects were discovered. The drug was previously expected to gain marketing approval from the U.S. Food and Drug Administration in July, but that decision will now be delayed by up to a year or more, if the drug is approved at all.

  • [By WWW.THESTREET.COM]

    Finally on Friday, Tiffany (TIF) reports, and Cramer is betting on positive news now that the company has an activist involved. He was also bullish on Amgen’s (AMGN) analyst meeting, saying investors should use any market weakness earlier in the week to buy.

  • [By Ben Levisohn]

    Biotech stocks have been particularly unloved during the past year, with the iShares Nasdaq Biotech Index ETF (IBB) gaining just 7% to the S&P 500′s 20% rise. Today, however, Amgen (AMGN) is getting a lot of love from the market after releasing Street beating earnings and reporting that its anti-cholesterol drug reduced heart attacks.

Top 10 Biotech Stocks To Watch For 2018: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Chris Dier-Scalise]

    On Thursday, the Vetr crowd downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from 4.5 stars (Strong Buy), which was issued two days ago, to 3.5 stars (Hold). Crowd sentiment for Alnylam at the time of the downgrade was edging positive, with 66 percent of Vetr user rating bullish.

  • [By Lisa Levin]

    Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares shot up 53 percent to $114.87 after the company impressed investors with encouraging data from a phase 3 clinical trial. Alnylam, a company dedicated towards treating a wide range of debilitating diseases through ribonucleic acid (RNA) interference (RNAi) therapeutics, said after Tuesday's market close that a phase 3 study called APOLLO met its primary efficacy endpoint and all secondary endpoints.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) jumped as much as 14.5% today after announcing earnings after the bell yesterday. As a development-stage biotech, it wasn’t the revenue or the earnings that caused the spike, but the progression of Allnylam’s pipeline.

Top 10 Biotech Stocks To Watch For 2018: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Paul Ausick]

    ArQule Inc. (NASDAQ: ARQL) dropped about 23% Friday, to post a new 52-week low of $1.13 after closing at $1.47 on Thursday. The stock’s 52-week high is $2.17. Volume was about 15 times the daily average of around 150,000 shares. The biopharmaceutical company said this morning that a phase 3 trial of a cancer drug did not meet the primary endpoint of improving overall survival.

Top 10 Biotech Stocks To Watch For 2018: Medivation Inc.(MDVN)

Advisors’ Opinion:

  • [By Scott Rubin]

    Big gainers on the day included Intersil Corp (NASDAQ: ISIL), which jumped 20 percent on news of a buyout, and Medivation (NASDAQ: MDVN), which added 20 percent on a deal with Pfizer (NYSE: PFE) related to its cancer drug. Cotiviti Holdings Inc (NYSE: COTV) lost around 9 percent in the wake of a mid-day sell-off and Marathon Oil Corporation (NYSE: MRO) fell 7 percent in the wake of a management shakeup.

  • [By Ben Levisohn]

    Macro considerations have continued to weigh on stocks whenever they’ve shown signs of life and consensus estimates for many of the large cap companies have been declining. With the sector’s underperformance, the delta in the average PEG ratio for biotech growth companies (excluding Medivation (MDVN)) compared to non-biotech growth companies is slightly wider than it’s been for most of the year. As such, we remain constructive on the sector. That said, while valuations are attractive on a relative basis, there remains some uncertainty for the group and we would not be surprised to see the volatility continue…

  • [By Monica Gerson]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Friday's regular session.

    PACCAR Inc (NASDAQ: PCAR) Aug16 52.5 Puts: 10000 @ ASK $1.70: 10k traded vs 335 OI: Earnings 7/26 $54.94 Ref
    Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Jul16 345 Puts: 949 @ ASK $8.70: 1003 traded vs 55 OI: Earnings 8/2 $360.20 Ref
    NVIDIA Corporation (NASDAQ: NVDA) Fri 6/24 47.0 Puts (Wkly) Sweep: 689 @ ASK $1.12: 3758 traded vs 136 OI: Earnings 8/4 $46.69 Ref
    Medivation Inc (NASDAQ: MDVN) Sep16 55.0 Puts: 4000 @ Above Ask! $3.40: 5303 traded vs 716 OI: Earnings 8/4 $59.44 Ref
    Expeditors International of Washington (NASDAQ: EXPD) Aug16 47.0 Puts Sweep: 950 @ ASK $1.35: 973 traded vs 381 OI: Earnings 8/2 $48.15 Ref

    Posted-In: Huge Put PurchasesNews Options Markets

  • [By Ben Levisohn]

    Last night, Bloomberg reported that Sanofi (SNY) had made a bid for Medivation (MDVN) but had been rebuffed, while noting that other companies–perhaps Gilead Sciences (GILD), Amgen (AMGN) or AstraZeneca (AZN)?–were also on the prowl. SunTrust Robinson Humphrey’s Peter Lawson explains why Medivation might be biotech’s most wanted:

  • [By Ben Levisohn]

    RBC’s Simos Simeonidis and Matthew Eckler try to find the right comparison for Pfizer’s (PFE) purchase of Medivation (MDVN):

    Scott Eisen/Bloomberg News

    We were obviously wrong with our Sector Perform rating: while we knew an M&A transaction was definitely a good possibility, we just could not get to this level of valuation using a realistic Xtandi model and thus could not recommend the stock. The only way for us to get to $81.50 (or even to $60-$70/share) would have been to assign very significant value to talazoparib. And we could not do that given the amount of available clinical evidence.Medivation shareholders who held on to their shares past the $50′s, did just that, were proven right and are now rewarded for it, since they believed that someone would be willing to pay for this asset just months ahead of Phase III data. The key question is why would a company be willing to part with what they claim/think may be a multibillion dollar drug that works in multiple cancers. We believe the obvious answer is because they’re smart and understand drug development risk better than most. We’ll know in a matter of months whether Pfizer/Medivation is like Amgen (AMGN)-Onyx (carfilzomib) or not.

Top 10 Biotech Stocks To Watch For 2018: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Thursday was Biogen Inc. (NASDAQ: BIIB) which traded down 4.6% at $279.08. The stocks 52-week range is $223.02 to $333.65. Volume was 3.4 million versus the daily average of 1.6 million shares.

  • [By Chris Lange]

    Biogen Inc. (NASDAQ: BIIB) had its short interest increase to 2.63 million shares from the previous 2.36 million. The stock closed Friday at $305.20, within a 52-week range of $223.02 to $333.65.

  • [By Ben Levisohn]

    Biogen (BIIB) has dropped 2.2% to $286.16 after getting cut to Market Perform from Outperform at Leerink, and to Equal Weight from Overweight at Morgan Stanley.

  • [By Todd Campbell]

    A new and highly anticipated study byCelgene Corp. (NASDAQ:CELG) shows that its promising multiple sclerosis drug could soon reshape the $19 billion multiple sclerosis market. On Friday, management reported that ozanimod met its primary endpoint for reducing MS relapses better than Biogen Inc.’s (NASDAQ:BIIB) Avonex, and importantly, it did so without any new safety risks.

  • [By WWW.THESTREET.COM]

    Breakups have the potential to create a lot of value. Just look at what Biogen (BIIB) did with its hemophilia franchise. Spun out as Bioverativ (BIVV) , shares started trading earlier this year. The stock has climbed some 23% on seemingly no news, Cramer noted.

Top 10 Biotech Stocks To Watch For 2018: ARIAD Pharmaceuticals Inc.(ARIA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Healthcare shares gained around 0.73 percent in trading on Monday. Meanwhile, top gainers in the sector included Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and VCA Inc (NASDAQ: WOOF).

Top 10 Safest Stocks For 2018

We spoke with the company Nvidia (NASDAQ:NVDA) in late June and we fell in love all over again. As an analyst who lives and dies by working through the earnings model to figure out earnings numbers it doesn’t get much better than Nvidia. The Street has been low, is currently low, and probably is still very low on the coming quarters as well. On a simple PE valuation with no fancy numbers we’re about to show you how this stock can easily be another double from here in the next 12 months.

We Give Nvidia Our Official Highest Rating: Love

We love it.

Top 10 Safest Stocks For 2018: Jacobs Engineering Group Inc.(JEC)

Advisors’ Opinion:

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Tuesday was Jacobs Engineering Group Inc. (NYSE: JEC) which rose about 9% to $64.92. The stocks 52-week range is $49.31 to $65.29. Volume was1.8 million compared to its average volume of less than 1 million.

  • [By Ben Levisohn]

    Lee offers 22 stocks that could benefit from the correlation trade: Western Digital (WDC), Xerox (XRX), First Solar, Ford Motor, Best Buy (BBY), PulteGroup (PHM), AutoNation (AN), Textron (TXT), Jacobs Engineering Group (JEC), Mosaic, BB&T (BBT), Fifth Third Bancorp (FITB),Loews (L), Regions Financial (RF), KeyCorp (KEY), Comerica (CMA), Leucadia National (LUK), Zions Bancorp (ZION), Valero Energy (VLO), Marathon Oil, Cardinal Health (CAH), and Pepco Holdings (POM).

Top 10 Safest Stocks For 2018: China Automotive Systems, Inc.(CAAS)

Advisors’ Opinion:

  • [By Monica Gerson]

    China Automotive Systems, Inc. (NASDAQ: CAAS) is projected to post its quarterly earnings at $0.20 per share on revenue of $108.22 million.

    Affimed NV (NASDAQ: AFMD) is projected to post a quarterly loss at $0.18 per share on revenue of $1.71 million.

Top 10 Safest Stocks For 2018: CenturyLink, Inc.(CTL)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Originally a rural telecom, CenturyLink (CTL) has grown via acquisitions to become a major provider of broadband, voice, video, and data.

    It now provides services residential and business customers over a 250,000-route-mile US fiber network and a 300,000 mile international network.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Monday CenturyLink, Inc. (NYSE: CTL) which rose over 8% to $15.88. The stocks 52-week range is $13.16 to $27.61. Volume was over 25 million compared to its average volume of 14.6 million.

  • [By Paul Ausick]

    CenturyLink Inc. (NYSE: CTL) dropped about 7.8% Monday to post a new 52-week low of $17.07 after closing at $18.51 on Friday. The 52-week high is $30.39. Volume was around 21 million, about double the daily average of around 11 million. The company’s $34 billion acquisition of Level 3 Communications received FCC approval, but the company was hit with a charge of securities fraud.

Top 10 Safest Stocks For 2018: FIRST REPUBLIC BANK(FRC)

Advisors’ Opinion:

  • [By Lisa Levin] Related WFC Why Bank ETFs Fell On Friday Despite Decent Earnings Phil's Stock World: Funtime Friday Earnings Season Starts Today Rising Book Values and Margins of Safety (GuruFocus)
    Related C Earnings Preview: Financial Giants BAC, GS, And MS Report Q2 Results This Week Why Bank ETFs Fell On Friday Despite Decent Earnings Palo Capital, Inc. Buys Citigroup Inc, Schlumberger, NetApp Inc, Sells Citrix Systems Inc, … (GuruFocus) Companies Reporting Before The Bell
    Wells Fargo & Co (NYSE: WFC) is estimated to report quarterly earnings at $1.02 per share on revenue of $22.51 billion.
    Citigroup Inc (NYSE: C) is projected to report quarterly earnings at $1.26 per share on revenue of $17.71 billion.
    JPMorgan Chase & Co. (NYSE: JPM) is expected to report quarterly earnings at $1.65 per share on revenue of $25.61 billion.
    PNC Financial Services Group Inc (NYSE: PNC) is projected to report quarterly earnings at $2.02 per share on revenue of $4.00 billion.
    First Republic Bank (NYSE: FRC) is estimated to report quarterly earnings at $1.1 per share on revenue of $675.70 million.
    First Horizon National Corp (NYSE: FHN) is projected to report quarterly earnings at $0.28 per share on revenue of $337.89 million.

     

  • [By Lisa Levin]

    Some of the stocks that may grab investor focus today are:

    Wall Street expects Citigroup Inc (NYSE: C) to report quarterly earnings at $1.26 per share on revenue of $17.71 billion before the opening bell. Citigroup shares rose 0.30 percent to $67.22 in after-hours trading.
    Analysts are expecting JPMorgan Chase & Co. (NYSE: JPM) to have earned $1.65 per share on revenue of $25.61 billion in the latest quarter. JPMorgan will release earnings before the markets open. JPMorgan shares gained 0.48 percent to $93.55 in after-hours trading.
    Cyberark Software Ltd (NASDAQ: CYBR) lowered its guidance for the second quarter. The company now expects total revenue of $57.0 million to $57.5 million, versus earlier guidance of $61.0 million to $62.0 million. Cyberark shares dipped 17.65 percent to $42.00 in the after-hours trading session.
    Before the opening bell, First Republic Bank (NYSE: FRC) is projected to report quarterly earnings at $1.1 per share on revenue of $675.70 million. First Republic Bank shares dropped 0.80 percent to close at $101.35 on Thursday.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Top 10 Safest Stocks For 2018: Spark Therapeutics, Inc.(ONCE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Spark Therapeutics Inc (NASDAQ: ONCE) were down 36 percent to $47.08 on preliminary SPK-8011 trial data.

    Athenex Inc (NASDAQ: ATNX) was down, falling around 13 percent to $13.95. Almirall and Athenex reported a strategic partnership to develop and commercialize KX2-391 in the U.S. and Europe.

  • [By Jim Robertson]

    On Wednesday, our Elite Opportunity Pronewsletter suggested going long again on small cap gene therapy stock Spark Therapeutics (NASDAQ: ONCE):

    Financially, Spark Therapeutics has over $300M in cash on the books and no debt to speak of yet, which equates to a share price of just over four times cash. The Company has generated over $20M in revenue for the trailing twelve months, and although the Company is expected to continue to lose money for the next few years, any strong clinical data that hits the tape could rocket shares of ONCE overnight, just like we’ve seen with so many others over the years.

  • [By Paul Ausick]

    Spark Therapeutics Inc. (NASDAQ: ONCE) dropped 44% Monday to post a new 52-week low of $41.06 after closing at $73.38 on Friday. The 52-week high is $91.75. Volume was around 13.5 million, nearly 30 times the daily average of about 480,000. The company’s hemophilia A drug posted disappointing trial results.

  • [By Chris Lange]

    Spark Therapeutics Inc. (NASDAQ: ONCE) saw its shares take a big step back on Monday after the firm reported less than favorable results at the American Society of Hematology (ASH) annual meeting. Analysts have taken this opportunity to weigh in on the stock:

Top 10 Safest Stocks For 2018: Hanesbrands Inc.(HBI)

Advisors’ Opinion:

  • [By Paul Ausick]

    Hanesbrands Inc. (NYSE: HBI) dropped about 0.6% on Thursday to post a new 52-week low of $21.41 after closing at $21.53 on Wednesday. The stock’s 52-week high is $31.36. Volume was about a third the daily average of around 6 million shares. The company had no specific news Thursday.

  • [By Rich Duprey]

    If a stock falls hard, particularly one with a durable name in its industry, it could be an opportunity to pick up shares on the cheap. But sometimes, a stock trades at a discount for a very good reason, so let’s take a look at Whirlpool (NYSE:WHR), Hanesbrands (NYSE:HBI), and Vista Outdoor (NYSE:VSTO) to see if they are good values at these lower prices — or just value traps.

  • [By Paul Ausick]

    Hanesbrands Inc. (NYSE: HBI) dropped about 5.9% on Wednesday to post a new 52-week low of $21.50 after closing at $22.86 on Tuesday. The stock’s 52-week high is $31.36. Volume of about 31 million was more than 7 times the daily average of 4.5 million. The company had no specific news.

  • [By Ben Levisohn]

    Today, the Wall Street Journal reported that Kate Spade & Co is considering a sale of the company, following pressure from activist investors given the volatile performance ever since Kate Spade became a mono brand company over 2 years ago. The article cites thatKate Spade has hired an investment bank and has reached out to possible buyers (including other retailers) althoughKate Spade has not responded. This comes at a time when brand houses like VF Corp. (VFC), PVH Corp. (PVH), Hanesbrands (HBI), Michael Kors Holdings (KORS), and Coach have said they are looking to make a branded acquisition, andKate Spade could be one of the strongest candidates. While other brands are seeing negative comps, pulling back on wholesale exposure or restructuring,Kate Spade continues to grow.

Top 10 Safest Stocks For 2018: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Chris Lange]

    Biogen Inc. (NASDAQ: BIIB) had its short interest increase to 2.63 million shares from the previous 2.36 million. The stock closed Friday at $305.20, within a 52-week range of $223.02 to $333.65.

  • [By Ben Levisohn]

    Biogen (BIIB) has dropped 2.2% to $286.16 after getting cut to Market Perform from Outperform at Leerink, and to Equal Weight from Overweight at Morgan Stanley.

  • [By WWW.MONEYSHOW.COM]

    Biogen (BIIB)

    Biogen discovers, develops and delivers innovative therapies for the treatment of neurodegenerative diseases and autoimmune disorders.

  • [By WWW.THESTREET.COM]

    Breakups have the potential to create a lot of value. Just look at what Biogen (BIIB) did with its hemophilia franchise. Spun out as Bioverativ (BIVV) , shares started trading earlier this year. The stock has climbed some 23% on seemingly no news, Cramer noted.

  • [By George Budwell]

    Shares of theDanish drugmaker Forward Pharma A/S (NASDAQ:FWP) gained 48.2% yesterday as the result of a settlement and licensing deal with Biogen (NASDAQ:BIIB)involving an ongoing patent dispute over the multiple sclerosis drug Tecfidera. Per the terms of the deal, Biogen will fork overa non-refundable$1.25 billion licensing fee, and possibly pay 10% to 20% royalties on Tecfidera’snet sales to Forward starting in 2021.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Monday was Biogen Inc. (NASDAQ: BIIB) which traded down nearly 4% at $329.58. The stocks 52-week range is $244.28 to $348.84. Volume was 1.2 million matching the daily average of 1.2 million shares.

Top 10 Safest Stocks For 2018: Flowers Foods, Inc.(FLO)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Consumers across the nation know Flowers Foods (NYSE:FLO) from its Wonder bread, Tastykake snack cakes, and Nature’s Own bakery brands. Yet the truly novel thing about Flowers is how it has done such a good job of building up a national presence in an industry that is typically dominated by local competition. Coming into Monday’s fourth-quarter financial report, Flowers investors were hoping to see at least some growth in sales and earnings, but the bakery company wasn’t able to deliver the pace of expansion that most shareholders really want to see.

  • [By Lisa Levin]

    Some of the stocks that may grab investor focus today are:

    Wall Street expects Dr Pepper Snapple Group Inc. (NYSE: DPS) to report quarterly earnings at $1.06 per share on revenue of $1.57 billion before the opening bell. Dr Pepper Snapple shares fell 0.07 percent to close at $93.49 on Monday.
    Analysts expect American International Group Inc (NYSE: AIG) to post quarterly earnings at $1.01 per share on revenue of $12.87 billion after the closing bell. AIG shares gained 0.38 percent to $66.39 in after-hours trading.
    Flowers Foods, Inc. (NYSE: FLO) reported in-line earnings for its fourth quarter, while sales missed expectations. Flowers Foods shares fell 1.87 percent to $20.45 in the after-hours trading session.
    Before the markets open, Diebold Nixdorf Inc (NYSE: DBD) is projected to report its quarterly earnings at $0.32 per share on revenue of $1.31 billion. Diebold Nixdorf shares slipped 0.73 percent to close at $27.20 on Monday.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Top 10 Safest Stocks For 2018: Valhi Inc.(VHI)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Thursday, basic materials shares slipped by 0.61 percent. Meanwhile, top losers in the sector included Valhi, Inc. (NYSE: VHI), down 13 percent, and LSB Industries, Inc. (NYSE: LXU), down 7 percent.

Top 10 Safest Stocks For 2018: Gogo Inc.(GOGO)

Advisors’ Opinion:

  • [By Peter Graham]

    The Q4 2016 earnings report for small capin-flight WiFi stockGogo Inc (NASDAQ: GOGO) is scheduled for before the market opens onMonday (February 27th). Last summer, American Airlines did a deal with rival ViaSat, Inc (NASDAQ: VSAT) to provide Internet access on about 100 new Boeing jets. To add to the turbulence, Moody’s Investors Service assigned a B3 Corporate Family Rating, a B3-PD Probability of Default Rating and a SGL-2 Speculative Grade Liquidity Rating to Gogo Inc plus assigned a B2 (LGD3) rating to the Company’s $500 senior secured note offering (after a planned sale of $525 millionin junk bonds fell through). The Ratings Action noted:

  • [By Steve Symington]

    Shares of Gogo Inc. (NASDAQ:GOGO) were up 18.3% as of 1:30 p.m. EST Monday after the in-flight connectivity specialist announced stronger-than-expected fourth-quarter 2016 results.

  • [By Lee Jackson]

    Gogo Inc. (NASDAQ: GOGO) had a director purchasing a total of 300,000 shares at $9.69 per share. The total for the purchase was posted at $3 million.Gogo provides communications services to the commercial and business aviation markets in the United States and internationally. Itsstock was trading on Friday at $8.85.

  • [By Ashley Moore]

    We’ve compiled a list of the most heavily shorted stocks to show you which stocks have the most negative sentiment on the market…

    Company Name (Ticker)Short FloatShare PriceHanwha Q Cells Co. Ltd. (Nasdaq ADR: HQCL)98.52%$ 8.88Renren Inc. (NYSE: RENN)91.59%$ 8.53Weight Watchers International Inc. (NYSE: WTW)67.92%$12.57INSYS Therapeutics Inc. (Nasdaq: INSY)66.71%$10.74Twilio Inc. (NYSE: TWLO)66.34%$33.17Nutanix Inc. (Nasdaq: NTNX)65.65%$31.96Fitbit Inc. (NYSE: FIT)55.15%$ 6.06Weibo Corp. (Nasdaq ADR: WB)53.83%$55.26RPC Inc. (NYSE: RES)53.62%$21.19Straight Path Communications Inc. (NYSEMKT: STRP)49.27%$34.79Momo Inc. (Nasdaq ADR: MOMO)48.63%$26.80Seritage Growth Properties (NYSE: SRG)46.91%$44.87Lannett Company Inc. (NYSE: LCI)45.46%$23.00Gogo Inc. (Nasdaq: GOGO)43.98%$ 9.10Altisource Portfolio Solutions SA (Nasdaq: ASPS)42.78%$22.73Cheetah Mobile Inc. (NYSE ADR: CMCM)40.86%$10.00

    Some investors think the only way to profit from the stock market is to buy stocks and wait for the price to rise. However, these investors are missing out on the massive profit opportunity that comes from shorting stocks.

  • [By Dan Caplinger]

    Monday started the new week on a positive note, as the stock market once again recovered from early declines to post advances. The Dow Jones Industrials extended its string of record closes to 12 consecutive days in the wake of favorable comments from Warren Buffett about the valuation of the market. Moves within the Trump administration to transfer spending to the Defense Department also bolstered the overall market mood. In addition, good news from certain companies helped to sustain positive sentiment overall, and Advanced Micro Devices (NASDAQ:AMD), Windstream Holdings (NASDAQ:WIN), and Gogo (NASDAQ:GOGO) were among the top performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.

  • [By Lisa Levin]

    Shares of Gogo Inc (NASDAQ: GOGO) got a boost, shooting up 19 percent to $10.85 after the company reported a narrower-than-expected quarterly loss.

Top 10 Biotech Stocks To Buy For 2018

Starting with a simple tweet on September 21st, 2015, Hillary Clinton has been pummeling Biotech stocks since her Presidential Campaign first began.  In fact, Clinton has caused dramatic drops in the iShares Nasdaq Biotechnology ETF (IBB) at least three times in the past 14 months. The thought of Clinton winning the presidency, and the corresponding assault on the Biotech sector, was a big reason the IBB lost over 23% from 9/21/15 through Election Day this November — underperforming the S&P 500 index by over 30%. Over Thanksgiving, Todd Hagopian made a strong case that Biotech is the sector that will benefit most from Donald Trump’s Presidency.

Todd Hagopian expects Biotech stocks to flourish during Donald Trump’s Presidency. (Photo by Drew Angerer/Getty Images)

Todd started his Biotech fund at Marketocracy in March, 2011. His returns have averaged 26.03% since then, which compares nicely to the S&P 500’s 11.58% return over the same period. Over the last five and three year periods, he did better than the top U.S. Equity fund manager. Before taking anyone’s investment advice, you should always check out their track record. Here is Todd’s.

Top 10 Biotech Stocks To Buy For 2018: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Paul Ausick]

    ArQule Inc. (NASDAQ: ARQL) dropped about 23% Friday, to post a new 52-week low of $1.13 after closing at $1.47 on Thursday. The stock’s 52-week high is $2.17. Volume was about 15 times the daily average of around 150,000 shares. The biopharmaceutical company said this morning that a phase 3 trial of a cancer drug did not meet the primary endpoint of improving overall survival.

Top 10 Biotech Stocks To Buy For 2018: ARIAD Pharmaceuticals Inc.(ARIA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Healthcare shares gained around 0.73 percent in trading on Monday. Meanwhile, top gainers in the sector included Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and VCA Inc (NASDAQ: WOOF).

Top 10 Biotech Stocks To Buy For 2018: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Breakups have the potential to create a lot of value. Just look at what Biogen (BIIB) did with its hemophilia franchise. Spun out as Bioverativ (BIVV) , shares started trading earlier this year. The stock has climbed some 23% on seemingly no news, Cramer noted.

  • [By George Budwell]

    Shares of theDanish drugmaker Forward Pharma A/S (NASDAQ:FWP) gained 48.2% yesterday as the result of a settlement and licensing deal with Biogen (NASDAQ:BIIB)involving an ongoing patent dispute over the multiple sclerosis drug Tecfidera. Per the terms of the deal, Biogen will fork overa non-refundable$1.25 billion licensing fee, and possibly pay 10% to 20% royalties on Tecfidera’snet sales to Forward starting in 2021.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Monday was Biogen Inc. (NASDAQ: BIIB) which traded down nearly 4% at $329.58. The stocks 52-week range is $244.28 to $348.84. Volume was 1.2 million matching the daily average of 1.2 million shares.

  • [By Todd Campbell]

    A new and highly anticipated study byCelgene Corp. (NASDAQ:CELG) shows that its promising multiple sclerosis drug could soon reshape the $19 billion multiple sclerosis market. On Friday, management reported that ozanimod met its primary endpoint for reducing MS relapses better than Biogen Inc.’s (NASDAQ:BIIB) Avonex, and importantly, it did so without any new safety risks.

  • [By Chris Lange]

    Biogen Inc. (NASDAQ: BIIB) had its short interest increase to 2.63 million shares from the previous 2.36 million. The stock closed Friday at $305.20, within a 52-week range of $223.02 to $333.65.

Top 10 Biotech Stocks To Buy For 2018: Medivation Inc.(MDVN)

Advisors’ Opinion:

  • [By Monica Gerson]

    Medivation Inc (NASDAQ: MDVN) is said to have spurned recent takeover approach from France’s Sanofi SA (ADR) (NYSE: SNY), according to sources as reported by Bloomberg on Tuesday. Sanofi wants Medivation’s treatments for hard-to-cure cancers, the sources said. Medivation shares surged 8.46 percent to $49.60 in the after-hours trading session, while Sanofi shares fell 0.59 percent to $42.02 in after-hours trading.

  • [By Ben Levisohn]

    Last night, Bloomberg reported that Sanofi (SNY) had made a bid for Medivation (MDVN) but had been rebuffed, while noting that other companies–perhaps Gilead Sciences (GILD), Amgen (AMGN) or AstraZeneca (AZN)?–were also on the prowl. SunTrust Robinson Humphrey’s Peter Lawson explains why Medivation might be biotech’s most wanted:

  • [By Ben Levisohn]

    Well, it looks like Medivation (MDVN) now has five suitors after reports that Amgen (AMGN) is joining Pfizer (PFE), Sanofi (SNY), AstraZeneca (AZN) and Novartis (NVS) in considering a bid. Maxim’s Jason Kolbert and Jason McCarthy offer their thoughts:

    Medivation reports tonight at 4:30pm…

    We expect the focus to be on the recent proposals from Sanofi (SNY $38.75- NR); Pfizer (PFE $33.40 -NR), AstraZeneca (AZN $28.26-NR) and just today, Amgen (AMGN – $154.18 – NR)…

    Medivation is returning to new highs as suitors line up to make acquisition bids. In this scenario what is the right discount rate for modeling purposes?

    We believe our model for Xtandi revenues is good, therefore we review our risk rating and determine the following: 30% = $47 15% = $76 10% = $99

    With Medivation’s board having now said No to anything less than $65 per share, it suggests to us that the stability and predictability of Xtandi’s revenues is greater than we thought, the risk is lower. Our intermediate risk rating is 15% or $76 fair value.

    Shares of Medivation rose 0.3% to $59.22 today, while Pfizer gained 0.5% to $33.56, Sanofi fell 0.5% to $39.07, AstraZeneca dropped 0.6% to $39.07, Novartis declined 0.3% to $74.12, and Amgen ticked up 0.1% to $154.25.

     

  • [By Scott Rubin]

    Big gainers on the day included Intersil Corp (NASDAQ: ISIL), which jumped 20 percent on news of a buyout, and Medivation (NASDAQ: MDVN), which added 20 percent on a deal with Pfizer (NYSE: PFE) related to its cancer drug. Cotiviti Holdings Inc (NYSE: COTV) lost around 9 percent in the wake of a mid-day sell-off and Marathon Oil Corporation (NYSE: MRO) fell 7 percent in the wake of a management shakeup.

Top 10 Biotech Stocks To Buy For 2018: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Cory Renauer]

    Treating diseases that have a genetic component by altering the expression of the responsible genes is a promising new field of medicine, but it has been much less straightforward than biopharmaceutical companies had expected. Two contenders in this area, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS), saw a mix of setbacks and success in 2016.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) jumped as much as 14.5% today after announcing earnings after the bell yesterday. As a development-stage biotech, it wasn’t the revenue or the earnings that caused the spike, but the progression of Allnylam’s pipeline.

  • [By Chris Dier-Scalise]

    On Thursday, the Vetr crowd downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from 4.5 stars (Strong Buy), which was issued two days ago, to 3.5 stars (Hold). Crowd sentiment for Alnylam at the time of the downgrade was edging positive, with 66 percent of Vetr user rating bullish.

  • [By Lisa Levin]

    Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares shot up 53 percent to $114.87 after the company impressed investors with encouraging data from a phase 3 clinical trial. Alnylam, a company dedicated towards treating a wide range of debilitating diseases through ribonucleic acid (RNA) interference (RNAi) therapeutics, said after Tuesday's market close that a phase 3 study called APOLLO met its primary efficacy endpoint and all secondary endpoints.

Top 10 Biotech Stocks To Buy For 2018: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Johanna Bennett]

    Shares of Amgen (AMGN) led the drop in the S&P 500 today falling almost 6.4% to close at $168.61 after the drug maker unveiledlong-awaited data on its anti-cholesterol drug Repatha.

    Can shares of Amgen rebound from todays selloff?

    Yes, is the answer from RBC Capital Management analyst Michael Yee. He argues that the drug makers share price can grind back up if access to Repatha increases over the next few quarters. Earlier today, Amgen released data from an outcome study that missed expectations, leading some analyst to predict that health plans will continue to restrict access to the drug.

    As Yee writes:

    A number of key developments midday at the ACC conference that should shed increased confidence that Repatha reimbursement and utilization will continue to increase over time driving a new growth driver for AMGN and increased confidence in a new product cycle. If reimbursement does start to open up over next few quarters (tracking IMS scripts and other datapoints) and AMGN manages their execution on quarters/guidance – stock should recover off today’s overreaction reflecting high expectations

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest increase to 7.78 million shares from the previous level of 7.38 million. Shares closed most recently at $145.34, in a 52-week trading range of $133.64 to $176.85.

  • [By WWW.THESTREET.COM]

    That’s why Cramer said he’ll be listening for news coming from Celgene (CEL) , Amgen (AMGN) , Allergan (AGN) , an Action Alerts PLUS holding, and Regenron (REGN) , all of which are set to present. Of the four, Cramer said he’s sticking with Allergan and Amgen.

  • [By Tom Gentile]

    After the Senate scored the votes on Tuesday to review a plan for repealing or repealing and replacing what’s come to be known as Obamacare, we saw a mixed-bag reaction from healthcare stocks. Even some of the bulletproof ones, like Amgen Inc. (Nasdaq: AMGN), closed lower from their opening highs.

  • [By Ben Levisohn]

    What do I mean? Regeneron’s dropped 14% during the last three months, the result of a patent suit with Amgen(AMGN) over its anti-cholesterol drug Praluent, which a judge had set it wouldn’t be able to sell in the U.S.Then last night, there was finally good news: Ajudge ordered a stay, which would allow Regeneron to sell Praluent, and resulted in a 2% pop in its shares last night after the market close. But then Regeneron reported earnings, and while profits of $3.04 cents a share metthe Street consensus, Regeneron missed on sales and offered disappointing guidance. That caused Regeneron shares to sink 2.1% in pre-open trading.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) is expected to report its most recent quarterly results on Wednesday. The consensus estimates call for $3.00 in EPS and $5.61 billion in revenue. Shares closed trading at $160.41 on Friday, in a 52-week range of $133.64 to $184.21. The consensus price target is $185.13.

Top 5 Biotech Stocks To Invest In 2018

President and CEO of Radius Health Inc (NASDAQ:RDUS) Jesper Hoiland bought 6,100 shares of RDUS on 09/15/2017 at an average price of $32.72 a share. The total cost of this purchase was $199,592.

Radius Health Inc is a science-driven biopharmaceutical company engaged in developing new therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases. Radius Health Inc has a market cap of $1.45 billion; its shares were traded at around $33.25 with and P/S ratio of 1445.63.

CEO Recent Trades:

President and CEO Jesper Hoiland bought 6,100 shares of RDUS stock on 09/15/2017 at the average price of $32.72. The price of the stock has increased by 1.62% since.

CFO Recent Trades:

CFO Jose Carmona bought 3,000 shares of RDUS stock on 09/14/2017 at the average price of $32.83. The price of the stock has increased by 1.28% since.

Directors and Officers Recent Trades:

10% Owner Growth N V Biotech bought 150,000 shares of RDUS stock on 09/14/2017 at the average price of $33.45. The price of the stock has decreased by 0.6% since.10% Owner Growth N V Biotech bought 50,000 shares of RDUS stock on 09/12/2017 at the average price of $35.42. The price of the stock has decreased by 6.13% since.10% Owner Growth N V Biotech bought 50,000 shares of RDUS stock on 09/05/2017 at the average price of $36.75. The price of the stock has decreased by 9.52% since.

For the complete insider trading history of RDUS, click here

Top 5 Biotech Stocks To Invest In 2018: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Paul Ausick]

    ArQule Inc. (NASDAQ: ARQL) dropped about 23% Friday, to post a new 52-week low of $1.13 after closing at $1.47 on Thursday. The stock’s 52-week high is $2.17. Volume was about 15 times the daily average of around 150,000 shares. The biopharmaceutical company said this morning that a phase 3 trial of a cancer drug did not meet the primary endpoint of improving overall survival.

Top 5 Biotech Stocks To Invest In 2018: Medivation Inc.(MDVN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Well, it looks like Medivation (MDVN) now has five suitors after reports that Amgen (AMGN) is joining Pfizer (PFE), Sanofi (SNY), AstraZeneca (AZN) and Novartis (NVS) in considering a bid. Maxim’s Jason Kolbert and Jason McCarthy offer their thoughts:

    Medivation reports tonight at 4:30pm…

    We expect the focus to be on the recent proposals from Sanofi (SNY $38.75- NR); Pfizer (PFE $33.40 -NR), AstraZeneca (AZN $28.26-NR) and just today, Amgen (AMGN – $154.18 – NR)…

    Medivation is returning to new highs as suitors line up to make acquisition bids. In this scenario what is the right discount rate for modeling purposes?

    We believe our model for Xtandi revenues is good, therefore we review our risk rating and determine the following: 30% = $47 15% = $76 10% = $99

    With Medivation’s board having now said No to anything less than $65 per share, it suggests to us that the stability and predictability of Xtandi’s revenues is greater than we thought, the risk is lower. Our intermediate risk rating is 15% or $76 fair value.

    Shares of Medivation rose 0.3% to $59.22 today, while Pfizer gained 0.5% to $33.56, Sanofi fell 0.5% to $39.07, AstraZeneca dropped 0.6% to $39.07, Novartis declined 0.3% to $74.12, and Amgen ticked up 0.1% to $154.25.

     

  • [By Ben Levisohn]

    Macro considerations have continued to weigh on stocks whenever they’ve shown signs of life and consensus estimates for many of the large cap companies have been declining. With the sector’s underperformance, the delta in the average PEG ratio for biotech growth companies (excluding Medivation (MDVN)) compared to non-biotech growth companies is slightly wider than it’s been for most of the year. As such, we remain constructive on the sector. That said, while valuations are attractive on a relative basis, there remains some uncertainty for the group and we would not be surprised to see the volatility continue…

  • [By Ben Levisohn]

    RBC’s Simos Simeonidis and Matthew Eckler try to find the right comparison for Pfizer’s (PFE) purchase of Medivation (MDVN):

    Scott Eisen/Bloomberg News

    We were obviously wrong with our Sector Perform rating: while we knew an M&A transaction was definitely a good possibility, we just could not get to this level of valuation using a realistic Xtandi model and thus could not recommend the stock. The only way for us to get to $81.50 (or even to $60-$70/share) would have been to assign very significant value to talazoparib. And we could not do that given the amount of available clinical evidence.Medivation shareholders who held on to their shares past the $50′s, did just that, were proven right and are now rewarded for it, since they believed that someone would be willing to pay for this asset just months ahead of Phase III data. The key question is why would a company be willing to part with what they claim/think may be a multibillion dollar drug that works in multiple cancers. We believe the obvious answer is because they’re smart and understand drug development risk better than most. We’ll know in a matter of months whether Pfizer/Medivation is like Amgen (AMGN)-Onyx (carfilzomib) or not.

Top 5 Biotech Stocks To Invest In 2018: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Yesterday, after markets closed, it was announced that US Federal District Court Judge Sue Robinson ruled to issue a permanent injunction against Praluent, the PCSK9 mAb for hypercholesterolemia from partners Regeneron and Sanofi, due to infringement of patents from Amgen. The court has imposed a 30-day suspension (stay) on the injunction to allow for settlement or appeal of the District Court decision. Sanofi and Regeneron have announced their intent to appeal the ruling to the US Court of Appeals for the Federal Circuit (CAFC). The injunction decision is consistent with our counter-consensus published views communicated on 25 January 2016 (“Downgrade to Sell on evidence of likely infringement of Amgen’s PCSK9 patents”) and subsequently. Based on consultation with expert legal counsel, we now put >75% probability Amgen will prevail on appeal and/or Praluent is ultimately removed from the US market, and/or Amgen achieves a settlement substantially in its favor. We currently model $3.3 bn in non-risk-adjusted 2022E US revenues for Praluent, while consensus models $1.2 bn in 2022E US revenues. We reiterate our view from 25 January 2016 to preferentially own Amgen, The Medicines Company (MDCO) (Buy), and Alnylam (ALNY) (Buy) over Regeneron for exposure to PCSK9 inhibitor market dynamics as outcomes trials approach.

  • [By Chris Dier-Scalise]

    On Thursday, the Vetr crowd downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from 4.5 stars (Strong Buy), which was issued two days ago, to 3.5 stars (Hold). Crowd sentiment for Alnylam at the time of the downgrade was edging positive, with 66 percent of Vetr user rating bullish.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) jumped as much as 14.5% today after announcing earnings after the bell yesterday. As a development-stage biotech, it wasn’t the revenue or the earnings that caused the spike, but the progression of Allnylam’s pipeline.

Top 5 Biotech Stocks To Invest In 2018: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Amgen (AMGN) has tumbled 3.6% to $158.65 after beating earnings forecasts but missing on sales.

    Buffalo Wild Wings (BWLD) has dropped 3% to $157.51 after its earnings fell short of the Street consensus.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest increase to 7.78 million shares from the previous level of 7.38 million. Shares closed most recently at $145.34, in a 52-week trading range of $133.64 to $176.85.

  • [By Ben Levisohn]

    Three biotech stocks–Alexion Pharmaceuticals (ALXN), Amgen (AMGN), and Celgene (CELG)–reported earnings since yesterday’s close. But just one has seen its shares head higher after the announcement.

  • [By WWW.THESTREET.COM]

    Finally on Friday, Tiffany (TIF) reports, and Cramer is betting on positive news now that the company has an activist involved. He was also bullish on Amgen’s (AMGN) analyst meeting, saying investors should use any market weakness earlier in the week to buy.

  • [By Todd Shriber, ETF Professor]

    Several big-name biotech companies step into the earnings confessional starting in the middle of the week, with Amgen, Inc. (NASDAQ: AMGN), Anthem Inc (NYSE: ANTM), and Celgene Corporation (NASDAQ: CELG) among the companies in play. That could bring opportunity with the  Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU) and the Direxion Daily S&P Biotech Bear 3X Shares (NYSE: LABD).

  • [By Chris Lange]

    Shares of Amgen Inc. (NASDAQ: AMGN) saw a handy gain to close out the week after the company won a Delaware court ruling that blocked Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) from selling their cholesterol-lowering drug in the United States. Essentially the court found that the drug Praluent actually infringed upon Amgens patents for its rival treatment Repatha.

Top 5 Biotech Stocks To Invest In 2018: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Biogen (BIIB) has dropped 2.2% to $286.16 after getting cut to Market Perform from Outperform at Leerink, and to Equal Weight from Overweight at Morgan Stanley.

  • [By George Budwell]

    Shares of theDanish drugmaker Forward Pharma A/S (NASDAQ:FWP) gained 48.2% yesterday as the result of a settlement and licensing deal with Biogen (NASDAQ:BIIB)involving an ongoing patent dispute over the multiple sclerosis drug Tecfidera. Per the terms of the deal, Biogen will fork overa non-refundable$1.25 billion licensing fee, and possibly pay 10% to 20% royalties on Tecfidera’snet sales to Forward starting in 2021.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Monday was Biogen Inc. (NASDAQ: BIIB) which traded down nearly 4% at $329.58. The stocks 52-week range is $244.28 to $348.84. Volume was 1.2 million matching the daily average of 1.2 million shares.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Thursday was Biogen Inc. (NASDAQ: BIIB) which traded down 4.6% at $279.08. The stocks 52-week range is $223.02 to $333.65. Volume was 3.4 million versus the daily average of 1.6 million shares.

  • [By Brian Orelli]

    While that’s fine for clinical trials, it may make it difficult for Ionis’ drugs to compete with drugs that work as well but don’t have side effects that need to be monitored. Of course, for Spinraza, which Biogen (NASDAQ:BIIB) and Ionis recently got approved for spinal muscular atrophy, side effects aren’t an issue because there aren’t any other treatment options at the moment.